CClinicalTrials.gg
CompletedNCT03966924Updated May 11, 2021Results posted

The PREFORM Study: Rotational Fractional Resection for Submental Contouring

An interventional study of Rotational fractional resection (1.5mm Diameter Device) in Skin Laxity and Lipodystrophy, sponsored by Recros Medica, Inc.. Completed at 1 site in United States. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Recros Medica, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of rotational fractional resection (RFR) to improve neck contouring. Rotational fractional resection is used to remove loose skin and fat.

Read the detailed description

This is a prospective, single-center, single-arm (non-randomized), interventional cohort, non-significant risk (NSR) study designed to investigate the efficacy and safety of Rotational Fractional Resection (skin resection and focal lipectomy) in patients with moderate to severe submental skin laxity. The total duration of study participation for each subject is approximately up to 4 months for each subject from the screening visit to the exit visit. The follow-up period will be approximately 3 months after the procedure. Eligible subjects will complete a total of 11 study visits: screening, procedure, and follow-up visits at 1, 4, 7, 14, 21, 30, 45, 60, and 90 days post-procedure.

02

Conditions studied

  • Skin Laxity
  • Lipodystrophy

Browse trials for

Keywords

  • submental
  • laxity
  • lipodystrophy
03

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy male or female
  • At least 30 years old
  • Moderate to severe submental laxity
  • Up to moderate submental lipodystrophy
  • Agree to maintain weight (±5%) for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Previous intervention to treat submental fat or skin laxity
  • Use of aspirin, ibuprofen, naproxen, or Vitamin E within 14 days of the procedure
  • Severe acne, cystic acne or acne scars on neck
  • Trauma of chin or neck area
  • Skin infection or rash on neck
  • Psoriasis, hyperpigmentation, eczema, rosacea or vitiligo
  • History of scarring
  • Body mass index (BMI) >30
  • Clinically significant bleeding disorder
  • Anemia, kidney disease, or liver disease
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Rotational fractional resection (1.5mm Diameter Device)

    Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)

    Device: Rotational fractional resection (1.5mm Diameter Device)

Interventions

  • DeviceRotational fractional resection (1.5mm Diameter Device)

    Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)

05

What researchers measure

Primary outcomes

  1. Number of Participants Who Had at Least One Grade Improvement on the Submental Skin Laxity Scale

    Physician investigator rated the submental laxity using the Submental Skin Laxity scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe)

    Time frame: 90 days post treatment

Secondary outcomes

  1. Number of Participants Who Were Satisfied With the Appearance of Their Neck and Jawline

    Subjects rated their satisfaction of the appearance of their neck and jawline on a Subject Satisfaction Questionnaire. Results reflect subjects who were satisfied ("somewhat satisfied," "satisfied," or "very satisfied").

    Time frame: 90 days post treatment

  2. Number of Participants With a One Grade Improvement on the Submental Lipodystrophy Scale

    Comparison of the submental fat before and after procedure using the Submental Skin Lipodystrophy scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe)

    Time frame: 90 days post treatment

06

Results

Posted Feb 11, 2021
Limitations and caveats
This study evaluated 1.5mm diameter skin resections, the first-generation prototype, in the submental area.

Participant flow

Participant flow — Overall Study
MilestoneRotational Fractional Resection (1.5mm Diameter Device)
Started2
Completed2
Not completed0

Outcome measures

PrimaryNumber of Participants Who Had at Least One Grade Improvement on the Submental Skin Laxity Scale

Physician investigator rated the submental laxity using the Submental Skin Laxity scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe)

Time frame:
90 days post treatment
Reported as:
Count of participants · Participants
Number of Participants Who Had at Least One Grade Improvement on the Submental Skin Laxity Scale
ParticipantsRotational Fractional Resection (1.5mm Diameter Device)
Number of Participants Who Had at Least One Grade Improvement on the Submental Skin Laxity Scale2
SecondaryNumber of Participants Who Were Satisfied With the Appearance of Their Neck and Jawline

Subjects rated their satisfaction of the appearance of their neck and jawline on a Subject Satisfaction Questionnaire. Results reflect subjects who were satisfied ("somewhat satisfied," "satisfied," or "very satisfied").

Time frame:
90 days post treatment
Reported as:
Count of participants · Participants
Number of Participants Who Were Satisfied With the Appearance of Their Neck and Jawline
ParticipantsRotational Fractional Resection (1.5mm Diameter Device)
Number of Participants Who Were Satisfied With the Appearance of Their Neck and Jawline2
SecondaryNumber of Participants With a One Grade Improvement on the Submental Lipodystrophy Scale

Comparison of the submental fat before and after procedure using the Submental Skin Lipodystrophy scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe)

Time frame:
90 days post treatment
Reported as:
Count of participants · Participants
Number of Participants With a One Grade Improvement on the Submental Lipodystrophy Scale
ParticipantsRotational Fractional Resection (1.5mm Diameter Device)
Number of Participants With a One Grade Improvement on the Submental Lipodystrophy Scale2

Adverse events

Collected over 90 days post treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotational Fractional Resection (1.5mm Diameter Device)0/2 (0%)0/2 (0%)1/2 (50%)
Most frequent other events
Most frequent other events
EventRotational Fractional Resection (1.5mm Diameter Device)
Skin irritationSkin and subcutaneous tissue disorders1/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rotational Fractional Resection (1.5mm Diameter Device)
Mean57 (55 to 59)
Sex: Female, Male
Sex: Female, Male(Participants)Rotational Fractional Resection (1.5mm Diameter Device)
Female2
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rotational Fractional Resection (1.5mm Diameter Device)
Hispanic or Latino0
Not Hispanic or Latino2
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rotational Fractional Resection (1.5mm Diameter Device)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
Submental Skin Laxity Scale score
Submental Skin Laxity Scale score(Participants)Rotational Fractional Resection (1.5mm Diameter Device)
Moderate1
Severe1
07

Study locations

1 site
  • Steve Yoelin, MD Medical Associates, Inc.
    Newport Beach, California 92663, United States
08

References and documents

Study documents

  • Study protocol · May 17, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03966924
Lead sponsor
Recros Medica, Inc.
Responsible party
Sponsor
First posted
May 29, 2019
Start date
Mar 20, 2019
Primary completion
Oct 16, 2019
Completion
Oct 16, 2019
Results posted
Feb 11, 2021
Last update
May 11, 2021

Study contacts

Robin McIntosh
study director · Recros Medica

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion